SHAREHOLDER ALERT: Barr Law Group Investigating VNDA, VLDR, RIDE, and ABT; Shareholders are Encouraged to Contact the Firm

 

National law firm Barr Law Group is investigating the actions of the officers and board of directors of Vanda Pharmaceuticals Inc., Velodyne Lidar, Inc., Lordstown Motors Corporation, and Abbott Laboratories.   If you are a current owner of shares of any of these stocks, contact leo@barrlaw.com or call (619) 400-4966.

 

  Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) Shareholder Lawsuit Update  

 

Barr Law Group is investigating Vanda Pharmaceuticals Inc. regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders. On March 10, 2021, Judge Frederic Block of the United States District Court for the Eastern District of New York issued an order denying the company's motion to dismiss in the pending securities class action, paving the way for litigation to proceed. According to the complaint against Vanda Pharmaceuticals for alleged violations of the Securities Exchange Act of 1934, defendants misled investors about the company's competitive advantage and hid that the company was engaged in a fraudulent scheme in which the company promoted the off-label use of two primary products that treat central nervous system disorders — Fanapt and Hetlioz. To learn more about this investigation and your rights, visit: https://barrlaw.com/investor-contact . Representation is contingency based, no out of pocket costs.

 

  Velodyne Lidar, Inc. (NASDAQ: VLDR) Shareholder Rights Investigation  

 

Barr Law Group is investigating Velodyne Lidar, Inc. regarding possible breaches of fiduciary duties and other violations of law, including securities claims on behalf of shareholders. On February 22, 2021, Velodyne announced that the Board had "removed David Hall as Chairman of the Board and terminated Marta Hall's employment as Chief Marketing Officer of the Company" after the Audit Committee's investigation "concluded that Mr. Hall and Ms. Hall each behaved inappropriately with regard to certain Board and Company processes, and failed to operate with respect, honesty, integrity, and candor in their dealings with Company officers and directors." In addition, the Company announced that Velodyne's Board formally censured Mr. Hall and Ms. Hall, but that they would remain directors of Velodyne.   On this news, Velodyne's common stock fell $3.14, or approximately 15%, to close at $17.97 per share on February 22, 2021, on unusually heavy trading volume. Additionally, Velodyne's warrants fell $1.47, or approximately 20%, to close at $5.90 per warrant on February 22, 2021. Velodyne's stock price has continued to fall, currently trading around $14 per share.   To learn more about this investigation and your rights, visit: https://barrlaw.com/investor-contact . Representation is contingency based, no out of pocket costs.

 

  Lordstown Motors Corporation (NASDAQ: RIDE) Shareholder Rights Investigation  

 

Barr Law Group is investigating Lordstown Motors Corporation regarding possible breaches of fiduciary duties and other violations of law by the company's officers and directors. On March 12, Hindenburg Research put out a report noting: "Lordstown is an electric vehicle SPAC with no revenue and no sellable product, which we believe has misled investors on both its demand and production capabilities."   Hindenburg also noted, "Our conversations with former employees, business partners and an extensive document review show that the company's orders are largely fictitious and used as a prop to raise capital and confer legitimacy."   On this news, Lordstown was down over 16%.   To learn more about this investigation and your rights, visit: https://barrlaw.com/investor-contact . Representation is contingency based, no out of pocket costs.

 

  Abbott Laboratories (NYSE: ABT) Shareholder Rights Investigation  

 

Barr Law Group is investigating Abbott Laboratories regarding possible breaches of fiduciary duties and other violations of law by the company's officers and directors. To learn more about this investigation and your rights, visit: https://barrlaw.com/investor-contact . Representation is contingency based, no out of pocket costs.

 

Concerned shareholders are encouraged to contact Leo Kandinov to learn more:

 

leo@barrlaw.com
(619) 400-4966
www.barrlaw.com  

 

Barr Law Group is a boutique law firm consisting of highly experienced and specialized litigators who represent investors in securities litigation and corporate governance matters. The firm would be happy to further discuss these matters, and any legal rights or remedies potentially available to you, at no charge.

 

Attorney Advertising. Past results do not guarantee a similar outcome.

 

Contact:

 

Leo Kandinov, Partner
leo@barrlaw.com
619-400-4966
501 W Broadway Suite 800
San Diego, CA 92101
www.barrlaw.com  

 

 

 

  Primary Logo 

 

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians.

BlinkLab states in its Wednesday (March 12) release that the study is the largest digital diagnostic trial for autism in the US, with its aim being to support the early detection of developmental conditions like autism.

The first patient test took place at PriMED Clinical Research in Dayton, Ohio. PriMED, a division of PriMED Physicians, is one of two clinical sites selected for the study’s initial phase, which is targeting 100 patients.

Keep reading...Show less
HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Signs Strategic Collaboration Agreement with Garmin Health

HeraMED Limited (ASX: HMD), a medical data and technology company leading the digital transformation of maternity care, is delighted to announce it has entered into a collaboration agreement with Garmin (NYSE: GRMN), a leading global provider of smartwatches and GPS-enabled products, aimed at enhancing remote pregnancy monitoring and expanding the range of health data available to expectant mothers and their healthcare providers.

Keep reading...Show less
Cardiologist wearing virtual reality glasses.

2 Biggest Medical Device ETFs in 2025

Exchange-traded funds (ETFs) are a popular investment strategy, and generally contain a variety of publicly traded companies under one stock symbol, often with a focus on a specific sector.

Depending on the ETF, investors may be able to track up-and-coming companies, get exposure to top firms or a mix of both. Aside from stocks, some ETFs also track commodities or bonds.

In the healthcare industry, medical device ETFs bring together companies that go to great lengths to develop pharmaceutical-based technology that can improve the lives of patients.

Keep reading...Show less
Cyclomedica

Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

Cyclopharm Limited (ASX: CYC) is pleased to announce the signing of a major contract with Hospital Corporation of America Healthcare (HCA), one of the largest single healthcare providers in the United States. This agreement marks a significant milestone for the company which will allow the deployment of Technegas® in up to 169 nuclear medicine departments across HCA’s extensive network.1

Keep reading...Show less
CONNEQT App Launches in USA as Pulse Deliveries Commence

CONNEQT App Launches in USA as Pulse Deliveries Commence

Cardiex Limited (CDX:AU) has announced CONNEQT App Launches in USA as Pulse Deliveries Commence

Download the PDF here.

Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities.

The groundbreaking developments in antifungal treatments specifically targeting women's health issues present a substantial market potential, resulting in rising investor interest in this rapidly evolving sector.

Despite comprising half the global population, women face unique health challenges that have historically received insufficient attention and investment. Among these health challenges, vaginal candidiasis stands out as a persistent and widespread issue affecting millions of women worldwide.

Keep reading...Show less

Latest Press Releases

Related News

×